MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Role and significance of C-reactive protein in stages of Parkinson’s disease

    R. Matmurodov, S. Jumanazarova, H. Daminova, K. Khalimova (Tashkent, Uzbekistan)

    Objective: To сomparative analysis of the amount of CRP in the blood serum of patients according to the stages of PD. Background: C-reactive protein (CRP)…
  • 2026 International Congress

    The Transcriptomic, Neurotransmitter, and Cell Type Signatures Underlying Pure Fatigue in Early-stage Parkinson’s Disease

    Y. Xiao, S. Wang, Y. Hou, R. Ou, C. Li, W. Song, X. Shi, X. Zhu, H. Shang (Chengdu, China)

    Objective: This study elucidates spatiotemporal functional connectivity of pure fatigue in early Parkinson’s disease (PD) and uncovering underlying gene expression profiles. Background: Fatigue is a…
  • 2026 International Congress

    Sex-Specific Differences in Parkinson’s Disease: A Retrospective Analysis of over 10,000 Patients from the Paracelsus-Elena Hospital, a Specialized Movement Disorder Clinic in Germany

    S. Weber, S. Schnell, H. Aust, C. Trenkwalder, B. Mollenhauer (Goettingen, Germany)

    Objective: To analyze sex differences in PD in a large cohort from a hospital specializing in PD and other movement disorders. Background: Sex differences in…
  • 2026 International Congress

    Movement Disorder Spectrum and Neurological Outcomes in Children with Neuronal Ceroid Lipofuscinosis

    A. Saini, S. Vaidya (chandigarh, India)

    Objective: To describe the spectrum of movement disorders and associated clinical, genetic, and radiological features in children with Neuronal Ceroid Lipofuscinosis (NCL) Background: NCLs are…
  • 2026 International Congress

    Impact of Multi-day Wearable Monitoring on Neurologists’ Assessment of Motor Fluctuations and Treatment Strategies in Parkinson’s Disease: A Real-World Study

    M. Borrell-Pichot, L. Pérez-Carasol, A. Campolongo, B. Pascual-Sedano, R. Martínez-Fernández, JA. Aibar-Rodríguez, J. Kulisevsky, I. Aracli-Bolaños (Barcelona, Spain)

    Objective: To assess the impact of wearable-device objective metrics on neurologists’ perception and therapeutic decisions in a real-world cohort of patients with Parkinson’s disease (PD).…
  • 2026 International Congress

    Power Spectral Density Increases Covary with Clinical Overstimulation During Dystonia Deep Brain Stimulation Programming

    P. Bisarad, M. Pascual, J. Kelbert, S. Chinander, R. Gelineau-Morel, C. Gorodetsky, A. Hewitt, T. Larsh, N. Lucente, J. O'Malley, L. van Derwerf, J. Hauptman, T. Sanger, F. Ponce, M. Kruer, J. Thompson (Phoenix, USA)

    Objective: To assess the role of local field potential (LFP) as an acute biomarker of maximal tolerable stimulation (MTS) in dystonia patients. Background: Dystonia is…
  • 2026 International Congress

    Levels of IgA and IgG concentrations by stage of Parkinson’s disease

    S. Jumaniyozov, R. Matmurodov, H. Daminova, S. Inoyatova (Tashkent, Uzbekistan)

    Objective: To study of IgA and IgG levels cerebrospinal fluid of patients with different stages of PD. Background: In the clinical course of Parkinson's disease…
  • 2026 International Congress

    RTN2 Variants Expand the ALS–Hereditary Spastic Paraplegia Disease Spectrum

    A. Orlacchio, S. Ramadan, M. Stasi, A. Meyyazhagan, G. Ribas, C. Evangelisti, M. Miele, R. Miyamoto, T. Kawarai, M. França Jr, J. Pedroso, O. Barsottini, H. Teive, S. Santi, E. Panza (Perugia, Italy)

    Objective: To investigate the clinical and molecular characteristics of amyotrophic lateral sclerosis (ALS) families carrying variants in the RTN2 gene (SPG12), associated with hereditary spastic…
  • 2026 International Congress

    Continuous Subcutaneous Levodopa Therapy Improves Motor Fluctuations and Quality of Life in Parkinson’s Disease: Evidence from Meta-analysis of Clinical Trials

    K. Sarhan (Mansoura, Egypt)

    Objective: To evaluate the efficacy and safety of subcutaneous levodopa/carbidopa or prodrug infusions in reducing OFF-time and improving quality of life in patients with Parkinson’s…
  • 2026 International Congress

    Screening the Neuroprotective Potential of Mushroom Extracts in In Vitro Models of Parkinson’s Disease

    FD. Dustov, SB. Seo (Seoul, Republic of Korea)

    Objective: This study aimed to evaluate the neuroprotective potential of various mushroom extracts across four distinct cellular models of PD. Furthermore, we sought to identify…
  • « Previous Page
  • 1
  • …
  • 166
  • 167
  • 168
  • 169
  • 170
  • …
  • 208
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley